Company news
Zelluna Asa (OSL:ZLNA) news
Zelluna Asa news releases on 6ix. Latest, Aug 20, 2026: Zelluna ASA: Second Quarter 2026 results
Press releases & updates
Zelluna ASA: Second Quarter 2026 results
August 20, 2026
Zelluna receives Independent Data Monitoring Committee recommendation to continue patient enrolment in ZIMA-101
August 17, 2026
Zelluna ASA: Issuance of shares to Inven2 through set-off of settlement amounts under option and license agreement
August 4, 2026
Zelluna ASA awarded NOK 16 million Research Council of Norway grant
June 30, 2026
Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities
June 29, 2026
Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided
June 26, 2026
Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private Placement
June 17, 2026
Zelluna ASA: Private Placement and Retail Offering successfully placed
June 17, 2026
Zelluna ASA: First Quarter 2026 results
May 7, 2026
Zelluna ASA activates first clinical site for ZIMA-101, marking entry into clinical execution
May 6, 2026
Zelluna ASA – Annual General Meeting held on April 23, 2026
April 23, 2026
Zelluna ASA – Mandatory notification of trade
March 27, 2026
Zelluna to host Capital Markets Update 2026
March 26, 2026
Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026
March 26, 2026
Zelluna ASA [ZLNA]: Annual Report 2025
March 25, 2026
Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering
March 9, 2026
Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial
February 20, 2026
Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission
February 12, 2026
Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial
February 11, 2026
Zelluna ASA - Grant of Share Options
February 5, 2026
Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation
February 5, 2026
Zelluna promotes Emilie Gauthy to Chief Technology Officer
February 3, 2026
Zelluna ASA: Approval and publication of prospectus
January 15, 2026
Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours
December 17, 2025
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours
December 16, 2025
Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial
December 12, 2025
Zelluna ASA: Cancellation of subsequent repair offering
December 9, 2025
Zelluna ASA: New share capital registered
December 8, 2025
Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer
November 28, 2025
Zelluna ASA: Disclosure of large shareholding
November 27, 2025
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025
November 4, 2025
Zelluna ASA – Key information relating to subsequent offering
November 3, 2025
Zelluna ASA - Successful private placement and retail offering
November 3, 2025
Zelluna ASA – Contemplates private placement
November 3, 2025
Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General Business Update
November 3, 2025
Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-in-Human Trials in the UK
October 9, 2025
Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025
September 10, 2025
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update
August 20, 2025
Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation
August 14, 2025
Zelluna ASA - Grant of Share Options under Long-Term Incentive Program
July 3, 2025